Open Payments

Utah Valley Hospital

Type
Teaching hospital
Where
Provo, UT
Medicare CCN
460001
Received
$2,098,785 in 244 records, 2025 ($222,351 general, $1,876,433 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment35$222,351
2025Research payment209$1,876,433

By company

CompanyRecordsAmountYears
Eli Lilly and Company4$488,2342025
AstraZeneca Pharmaceuticals LP2$322,9312025
United Therapeutics Corporation108$313,7432025
Abbott Laboratories25$186,7352025
Boston Scientific Corporation25$170,0712025
Intuitive Surgical Operations, Inc.7$107,5302025
Novartis Pharmaceuticals Corporation5$101,7442025
Jenavalve Technology, Inc.3$83,2222025
BeiGene, Ltd.1$78,7902025
Boehringer Ingelheim Pharmaceuticals, Inc.22$65,2872025
National Marrow Donor Program4$40,8052025
APPLIED MEDICAL TECHNOLOGY INC12$38,8472025
KARL STORZ Endoscopy-America5$25,6502025
Grifols Therapeutics LLC1$21,7002025
BeOne Medicines Ltd.2$19,9852025
Verastem, Inc.1$9,1662025
Iovance Biotherapeutics, Inc.2$7,0002025
Ipsen Bioscience Inc.4$4,8062025
UROGEN PHARMA, INC.1$4,0002025
Astellas Pharma US Inc1$3,5002025
GE HEALTHCARE1$1,7372025
Zimmer Biomet Holdings, Inc.1$7402025
Organon Llc1$7002025
Kite Pharma, Inc.1$6502025
Smith+Nephew, Inc.1$4502025
Organogenesis Inc.1$4502025
Novo Nordisk Inc1$2502025
Alexion Pharmaceuticals, Inc.2$552025

By nature of payment

NatureRecordsAmount
Research payment209$1,876,433
Compensation for services other than consulting, including serving as faculty or as a speaker at a v7$124,027
Grant8$47,650
Royalty or License12$38,847
Space rental or facility fees (teaching hospital only)5$8,650
Consulting Fee1$1,737
Debt forgiveness1$740
Long term medical supply or device loan1$700

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-29UROGEN PHARMA, INC.$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentJELMYTO Drug, UROTHELIAL CANCER2025
2025-12-24United Therapeutics Corporation$2,539Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-12-24United Therapeutics Corporation$1,821Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-24United Therapeutics Corporation$1,641Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-23APPLIED MEDICAL TECHNOLOGY INC$2,753Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-12-17Grifols Therapeutics LLC$21,700Research paymentCash or cash equivalentAlbutein Biological, Critical Care MedicineThrombophilia Genetic Study in the USA: Thrombophilia occurrence study in patients admitted to a thrombosis clinic2025
2025-12-17Boehringer Ingelheim Pharmaceuticals, Inc.$1,246Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-12-16United Therapeutics Corporation$12,875Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-12-16Abbott Laboratories$3,300Research paymentCash or cash equivalentPORTICO Device, Structural HeartNCT04011722--Portico Next Generation Approval Study2025
2025-12-16Abbott Laboratories$3,000Research paymentCash or cash equivalentPORTICO Device, Structural HeartNCT04011722--Portico Next Generation Approval Study2025
2025-12-16United Therapeutics Corporation$1,000Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-12-16United Therapeutics Corporation$100Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-12-12KARL STORZ Endoscopy-America$11,000GrantCash or cash equivalent2025
2025-12-12KARL STORZ Endoscopy-America$6,000GrantCash or cash equivalent2025
2025-12-10Boehringer Ingelheim Pharmaceuticals, Inc.$1,195Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-12-10United Therapeutics Corporation$135Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-09Boston Scientific Corporation$7,107Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-12-09Boston Scientific Corporation$4,470Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-12-04Abbott Laboratories$10,000Research paymentCash or cash equivalentFREESTYLE LIBRE PRO Device, Diabetes CareISM2311001A--Continuous Glucose Monitoring System Comparison Study2025
2025-12-03Boehringer Ingelheim Pharmaceuticals, Inc.$9,088Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-12-02United Therapeutics Corporation$5,000Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-12-02Abbott Laboratories$2,250Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04198870--MitraClip REPAIR MR Study2025
2025-12-02United Therapeutics Corporation$150Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-12-02Abbott Laboratories$120Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04198870--MitraClip REPAIR MR Study2025
2025-11-26Abbott Laboratories$9,294Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04198870--MitraClip REPAIR MR Study2025
2025-11-26United Therapeutics Corporation$8,772Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-26United Therapeutics Corporation$2,764Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-11-26United Therapeutics Corporation$2,272Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-11-26United Therapeutics Corporation$1,468Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-20Verastem, Inc.$9,166Research paymentCash or cash equivalentRAMP 301 - GOG-30972025
2025-11-19Abbott Laboratories$672Research paymentCash or cash equivalentPORTICO Device, Structural HeartNCT04011722--Portico Next Generation Approval Study2025
2025-11-17APPLIED MEDICAL TECHNOLOGY INC$3,575Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-11-12United Therapeutics Corporation$7,484Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-11-12United Therapeutics Corporation$4,838Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-12United Therapeutics Corporation$3,373Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-12United Therapeutics Corporation$2,485Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-07Ipsen Bioscience Inc.$1,806Research paymentCash or cash equivalentA Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evalua2025
2025-11-07United Therapeutics Corporation$1,720Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)2025
2025-11-07Ipsen Bioscience Inc.$1,500Research paymentCash or cash equivalentA Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evalua2025
2025-11-06United Therapeutics Corporation$6,993Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-11-06United Therapeutics Corporation$576Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-11-06United Therapeutics Corporation$28Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-11-05Intuitive Surgical Operations, Inc.$21,029Research paymentCash or cash equivalentDa Vinci Surgical System Device, SURGERYIon registry study and IRB fees2025
2025-11-05Abbott Laboratories$16,174Research paymentCash or cash equivalent Device, Structural HeartNCT03904147--TRILUMINATE Pivotal Trial2025
2025-11-04Boston Scientific Corporation$100Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-11-03Abbott Laboratories$21,695Research paymentCash or cash equivalentNAVITOR Device, Structural HeartNCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation2025
2025-10-29United Therapeutics Corporation$10,000Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-10-29United Therapeutics Corporation$2,600Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-10-29United Therapeutics Corporation$1,500Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-10-29United Therapeutics Corporation$500Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-10-29Novartis Pharmaceuticals Corporation$402Research paymentIn-kind items and servicesA Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of 2025
2025-10-23United Therapeutics Corporation$13,154Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-10-22United Therapeutics Corporation$337Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-10-20Abbott Laboratories$75Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04177394--MitraClip EXPAND G4 Study2025
2025-10-17National Marrow Donor Program$11,495Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-10-15Boehringer Ingelheim Pharmaceuticals, Inc.$195Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-13APPLIED MEDICAL TECHNOLOGY INC$3,507Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-10-08United Therapeutics Corporation$135Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-10-07Boston Scientific Corporation$3,200Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-10-07Abbott Laboratories$1,500Research paymentCash or cash equivalentXIENCE SIERRA Device, VascularNCT03502811--The MitraClip EXPAND Study of the Next Generation of MitraClip Devices2025
2025-10-07Boston Scientific Corporation$575Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-10-07United Therapeutics Corporation$189Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-10-07Boston Scientific Corporation$100Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-10-06United Therapeutics Corporation$150Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-10-03GE HEALTHCARE$1,737Consulting FeeCash or cash equivalent2025
2025-10-01Boehringer Ingelheim Pharmaceuticals, Inc.$1,761Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-01Boehringer Ingelheim Pharmaceuticals, Inc.$600Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-09-30Iovance Biotherapeutics, Inc.$2,000Research paymentCash or cash equivalentAmtagvi Drug, OncologyIOV-EAP-4022025
2025-09-30Novo Nordisk Inc$250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-09-25United Therapeutics Corporation$4,500Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-09-25United Therapeutics Corporation$665Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-09-25United Therapeutics Corporation$517Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-09-23Boston Scientific Corporation$3,488Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIROWAN2025
2025-09-15Novartis Pharmaceuticals Corporation$14,005Research paymentCash or cash equivalentLEQVIO Drug, Cardiology/Vascular DiseasesA Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2025
2025-09-15APPLIED MEDICAL TECHNOLOGY INC$3,103Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-09-10United Therapeutics Corporation$2,698Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-09-10United Therapeutics Corporation$135Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-09-09Kite Pharma, Inc.$650Research paymentCash or cash equivalentYescarta Drug, CELLTA PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH P2025
2025-09-03United Therapeutics Corporation$21,000Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)2025
2025-09-03United Therapeutics Corporation$4,200Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)2025
2025-09-02Boehringer Ingelheim Pharmaceuticals, Inc.$4,748Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-08-31Iovance Biotherapeutics, Inc.$5,000Research paymentCash or cash equivalentAmtagvi Drug, OncologyIOV-EAP-4022025
2025-08-28Boehringer Ingelheim Pharmaceuticals, Inc.$1,600Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-08-27Intuitive Surgical Operations, Inc.$63,724Research paymentCash or cash equivalentDa Vinci Surgical System Device, SURGERYIon registry study and IRB fees2025
2025-08-27United Therapeutics Corporation$5,917Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-08-27United Therapeutics Corporation$2,992Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-08-26Boston Scientific Corporation$1,904Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIROWAN2025
2025-08-26Boston Scientific Corporation$500Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIROWAN2025
2025-08-21Boehringer Ingelheim Pharmaceuticals, Inc.$2,817Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-08-18Abbott Laboratories$9,404Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04198870--MitraClip REPAIR MR Study2025
2025-08-18APPLIED MEDICAL TECHNOLOGY INC$3,074Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-08-18Boehringer Ingelheim Pharmaceuticals, Inc.$300Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-08-14Boehringer Ingelheim Pharmaceuticals, Inc.$3,950Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-08-14Ipsen Bioscience Inc.$1,000Research paymentCash or cash equivalentA Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evalua2025
2025-08-14Ipsen Bioscience Inc.$500Research paymentCash or cash equivalentA Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evalua2025
2025-08-13Abbott Laboratories$17,007Research paymentCash or cash equivalent Device, Structural HeartNCT03904147--TRILUMINATE Pivotal Trial2025
2025-08-13United Therapeutics Corporation$540Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-08-04Abbott Laboratories$19,937Research paymentCash or cash equivalentNAVITOR Device, Structural HeartNCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation2025
2025-08-04Abbott Laboratories$290Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04177394--MitraClip EXPAND G4 Study2025
2025-08-04Alexion Pharmaceuticals, Inc.$10Research paymentIn-kind items and servicesAn Observational, Longitudinal, Prospective, Long term Registry of Patients with Hypophosphatasia2025
2025-08-01United Therapeutics Corporation$750Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-08-01United Therapeutics Corporation$100Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-08-01United Therapeutics Corporation$75Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-31United Therapeutics Corporation$1,300Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-07-31United Therapeutics Corporation$1,000Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-07-31United Therapeutics Corporation$1,000Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-07-31United Therapeutics Corporation$75Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-07-30Boehringer Ingelheim Pharmaceuticals, Inc.$1,846Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-07-30Boehringer Ingelheim Pharmaceuticals, Inc.$600Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-07-30Intuitive Surgical Operations, Inc.$383Research paymentCash or cash equivalentDa Vinci Surgical System Device, SURGERYIon registry study and IRB fees2025
2025-07-28BeOne Medicines Ltd.$13,860Research paymentCash or cash equivalentA Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Ac2025
2025-07-25AstraZeneca Pharmaceuticals LP$133,567Research paymentCash or cash equivalentA Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an2025
2025-07-23National Marrow Donor Program$10,150Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-07-23United Therapeutics Corporation$4,961Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-07-23United Therapeutics Corporation$337Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-07-22Boston Scientific Corporation$29,463Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-07-22United Therapeutics Corporation$20,942Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-22Boston Scientific Corporation$6,810Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIROWAN2025
2025-07-22Boehringer Ingelheim Pharmaceuticals, Inc.$2,700Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-07-22Boston Scientific Corporation$2,600Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-07-22Boston Scientific Corporation$83Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIROWAN2025
2025-07-14APPLIED MEDICAL TECHNOLOGY INC$3,348Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-07-13Boehringer Ingelheim Pharmaceuticals, Inc.$830Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-07-10Boston Scientific Corporation$2,000GrantIn-kind items and servicesGeneral - Tachy Device, General - Tachy_CRM2025
2025-07-08United Therapeutics Corporation$4,811Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-07-08United Therapeutics Corporation$3,110Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-07-07BeOne Medicines Ltd.$6,125Research paymentCash or cash equivalentA Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Ac2025
2025-07-04United Therapeutics Corporation$9,920Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-07-03United Therapeutics Corporation$2,500Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-03United Therapeutics Corporation$750Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-03United Therapeutics Corporation$189Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-03United Therapeutics Corporation$75Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-02Intuitive Surgical Operations, Inc.$1,150Research paymentCash or cash equivalentDa Vinci Surgical System Device, SURGERYIon registry study and IRB fees2025
2025-07-01Abbott Laboratories$80Research paymentIn-kind items and servicesNAVITOR Device, Structural HeartNCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation2025
2025-06-27Intuitive Surgical Operations, Inc.$742Research paymentCash or cash equivalentDa Vinci Surgical System Device, SURGERYIon registry study and IRB fees2025
2025-06-25Abbott Laboratories$9,626Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04198870--MitraClip REPAIR MR Study2025
2025-06-25United Therapeutics Corporation$2,992Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-06-20Boehringer Ingelheim Pharmaceuticals, Inc.$790Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-06-17Boston Scientific Corporation$8,879Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIROWAN2025
2025-06-17Boston Scientific Corporation$83Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIROWAN2025
2025-06-16APPLIED MEDICAL TECHNOLOGY INC$3,293Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-06-11United Therapeutics Corporation$4,009Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-06-11United Therapeutics Corporation$2,592Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-06-10Abbott Laboratories$500Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04177394--MitraClip EXPAND G4 Study2025
2025-06-09Abbott Laboratories$478Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04177394--MitraClip EXPAND G4 Study2025
2025-06-05Smith+Nephew, Inc.$450Space rental or facility fees (teaching hospital only)Cash or cash equivalentPICO Device, Negative Pressure Wound Therapy2025
2025-06-05Abbott Laboratories$20Research paymentIn-kind items and servicesNAVITOR Device, Structural HeartNCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation2025
2025-06-02United Therapeutics Corporation$750Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-06-02United Therapeutics Corporation$487Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-05-27Boston Scientific Corporation$26,616Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIROWAN2025
2025-05-27Novartis Pharmaceuticals Corporation$22,869Research paymentCash or cash equivalentLEQVIO Drug, Cardiology/Vascular DiseasesVictORION-INCLUSION: Evaluating INClisiran as a soLUtion to Improve LDL-C Management and cloSe Care Gaps in an Inclusive2025
2025-05-27KARL STORZ Endoscopy-America$900GrantCash or cash equivalent2025
2025-05-21United Therapeutics Corporation$7,242Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-05-21United Therapeutics Corporation$2,085Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-05-19APPLIED MEDICAL TECHNOLOGY INC$3,291Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-05-16Boehringer Ingelheim Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-05-14Intuitive Surgical Operations, Inc.$2,000Research paymentCash or cash equivalentDa Vinci Surgical System Device, SURGERYIon registry study and IRB fees2025
2025-05-12Abbott Laboratories$14,363Research paymentCash or cash equivalent Device, Structural HeartNCT03904147--TRILUMINATE Pivotal Trial2025
2025-05-09Boehringer Ingelheim Pharmaceuticals, Inc.$6,022Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-05-07United Therapeutics Corporation$4,067Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-05-07United Therapeutics Corporation$2,272Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-05-07United Therapeutics Corporation$2,175Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-05-07United Therapeutics Corporation$1,917Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-05-06United Therapeutics Corporation$2,655Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-05-06United Therapeutics Corporation$100Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-05-02BeiGene, Ltd.$78,790Research paymentCash or cash equivalentA Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Ac2025
2025-05-02Alexion Pharmaceuticals, Inc.$45Research paymentIn-kind items and servicesSTRENSIQ Biological, Rare DiseaseA Prospective Observational Sub Study of the Global Hypophosphatasia Registry to Evaluate the Potential Risk of Immune M2025
2025-04-30Jenavalve Technology, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-04-29KARL STORZ Endoscopy-America$750GrantCash or cash equivalentC-MAC Device, ANESTHESIOLOGY2025
2025-04-25National Marrow Donor Program$12,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-04-24United Therapeutics Corporation$1,300Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-04-24United Therapeutics Corporation$1,000Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-04-24United Therapeutics Corporation$650Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-04-24United Therapeutics Corporation$500Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-04-23Novartis Pharmaceuticals Corporation$24,162Research paymentIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular DiseasesA Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2025
2025-04-23United Therapeutics Corporation$2,698Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-04-23United Therapeutics Corporation$1,468Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-04-10United Therapeutics Corporation$750Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-04-10United Therapeutics Corporation$282Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-04-10United Therapeutics Corporation$253Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-04-10United Therapeutics Corporation$189Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-04-10United Therapeutics Corporation$75Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-04-09Boehringer Ingelheim Pharmaceuticals, Inc.$6,738Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-04-09United Therapeutics Corporation$2,802Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-04-09United Therapeutics Corporation$2,635Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-04-09United Therapeutics Corporation$1,336Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-04-09United Therapeutics Corporation$864Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-04-08Abbott Laboratories$21,500Research paymentCash or cash equivalentNAVITOR Device, Structural HeartNCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation2025
2025-04-08Boston Scientific Corporation$4,485Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-04-07APPLIED MEDICAL TECHNOLOGY INC$2,717Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-04-04United Therapeutics Corporation$11,880Research paymentCash or cash equivalentPULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER)2025
2025-04-03Organogenesis Inc.$450Space rental or facility fees (teaching hospital only)Cash or cash equivalentPURAPLY WOUND MATRIX Device, WOUND CARE2025
2025-03-25Boston Scientific Corporation$3,005Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2025
2025-03-19Zimmer Biomet Holdings, Inc.$740Debt forgivenessCash or cash equivalent2025
2025-03-17Abbott Laboratories$15,869Research paymentCash or cash equivalent Device, Structural HeartNCT03904147--TRILUMINATE Pivotal Trial2025
2025-03-12AstraZeneca Pharmaceuticals LP$189,363Research paymentCash or cash equivalentA Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice N2025
2025-03-12United Therapeutics Corporation$135Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-03-11Boehringer Ingelheim Pharmaceuticals, Inc.$830Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-03-10APPLIED MEDICAL TECHNOLOGY INC$3,342Royalty or LicenseCash or cash equivalentAMT Bridle Device, Enteral2025
2025-03-04United Therapeutics Corporation$5,500Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025

The latest 200 records of 244.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Utah CountyProvo city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Provo, UT, county Utah County, UT, state Utah; placed by its city name.

MeasurePlace (city or town)
Provo, UT
County
Utah County, UT
State
Utah
Population B01003114,766705,4003,392,331
Population, 2020 census P1115,162659,3993,271,616
Median age B0100223.625.832.0
Under 18 B0100118.7%31.6%27.8%
65 and over B010016.7%7.9%11.9%
Households B1100134,022203,0181,124,822
Foreign born B0500212.5%8.2%8.9%
Median household income B19013$64,171$100,671$95,166
Median family income B19113$73,450$110,986$109,675
Per capita income B19301$27,822$37,082$40,873
Poverty rate B1700123.0%8.7%8.5%
Unemployment rate B230255.1%3.8%3.6%
Civilian labor force B2302569,670363,7711,778,106
Mean commute (minutes) B0801318.422.622.1
Bachelor's degree or higher B1500345.2%44.4%37.7%
Housing units B2500135,944211,0661,223,468
Owner-occupied B2500339.4%68.3%70.2%
Renters B2500360.6%31.7%29.8%
Median home value B25077$467,200$538,700$489,400
Median gross rent B25064$1,193$1,541$1,496
White, not Hispanic B0300270.8%77.6%74.7%
Black B030021.1%0.7%1.1%
Hispanic or Latino B0300219.2%14.5%15.9%
Asian B030022.2%1.5%2.4%
American Indian and Alaska Native B030020.2%0.2%0.6%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Provo, UT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.